腎臓内科学部門
1.

Morishita Y, Yoshizawa H, Watanabe M, Ishibashi K, Muto S, Kusano E, Nagata D.
siRNAs targeted to Smad4 prevent renal fibrosis in vivo. Sci Rep 4, 6424 (2014)
https://www.ncbi.nlm.nih.gov/pubmed/25236771

2.

Myojo M, Nagata D, Fujita D, Kiyosue A, Takahashi M, Satonaka H, Morishita Y, AkimotoT, Nagai R, Komuro I, Hirata Y. Telmisartan activates endothelial nitric oxide synthase
via Ser1177 phosphorylation in vascular endothelial cells. PLoS One 9(5), e96948(2014)
https://www.ncbi.nlm.nih.gov/pubmed/24827148

3.

Komada T, Usui F, Kawashima A, Kimura H, Karasawa T, Inoue Y, Kobayashi M,Mizushina Y, Kasahara T, Taniguchi S, Muto S, Nagata D, Takahashi M. Role of NLRP3Inflammasomes for Rhabdomyolysis-induced Acute Kidney Injury. Sci Rep 2015 Jun
5;5:10901. doi: 10.1038/srep10901 (2015)

https://www.ncbi.nlm.nih.gov/pubmed/26045078
4.

Onishi A, Akimoto T, Urabe M, Hirahara I, Muto S, Ozawa K, Nagata D, Kusano E.
Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation byinterleukin-10. Lab Invest 95(12), 1353-1362 (2015)
https://www.ncbi.nlm.nih.gov/pubmed/26367488

5.

Murakami T, Takeda S, Kanazawa H, Ugajin A, Kijima S, Nakamura H, Imai T, Sugase
T, Horikoshi R, Kobayashi T, Akimoto T, Saito O, Nagata D. Subclinical growth of anarteriovenous fistula associated with renal biopsy: a case report. BMC Nephrol 17(1), 81(2016)
https://www.ncbi.nlm.nih.gov/pubmed/27406176

6.

Sugase T, Akimoto T, Kubo T, Imai T, Otani-Takei N, Miki T, Takeda S, Nukui A, Muto S,Morita T, Nagata D. Acute kidney injury associated with renal cell carcinoma complicatedby renal vein and inferior vena cava involvement. Intern Med 55(17), 2447-2452 (2016)
https://www.ncbi.nlm.nih.gov/pubmed/?term=Intern+Med.+2016%3B55(17)%3A244752

7.

Igarashi Y, Morishita Y, Yoshizawa H, Imai R, Imai T, Hirahara I, Akimoto T, Ookawara S,

Ishibashi K, Muto S, Nagata D. The association between soluble intercellular adhesion
molecule-1 levels in drained dialysate and peritoneal injury in peritoneal dialysis. Ren
Fail 39(1), 392-399 (2017)https://www.ncbi.nlm.nih.gov/pubmed/28201944
8.

Imai R, Akimoto T, Kimura T, Kohara M, Shimizu T, Oka K, Shuto M, Asakura M,Nagayama I, Takeda S, Yagisawa T, Muto S, Nagata D. Peritoneal dialysis andretroperitoneal laparoscopic radical nephrectomy: a favorable experience with a patientcomplicated by renal cell carcinoma. Clin Med Insights Case Rep 2017 Dec
10;10:1179547617746362. doi: 10.1177/1179547617746362 (2017)https://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Med+Insights+Case+Rep.+2017%3
B10%3A1179547617746362

9.

Kohara M, Masuda T, Shiizaki K, Akimoto T, Watanabe Y, Honma S, Sekiguchi C,Miyazawa Y, Kusano E, Kanda Y, Asano Y, Kuro-O M, Nagata D. Association between
circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS
One 12(6), e0178971 (2017)https://www.ncbi.nlm.nih.gov/pubmed/28582462

10. Iwazu Y, Muto S, Ioka T, Watanabe Y, Iwazu K, Kusano E, Nagata D. Multiple sclerosis
drug fingolimod induces thrombotic microangiopathy in deoxycorticosterone acetate/salt
hypertension. Hypertension 72(3), 776-784 (2018)https://www.ncbi.nlm.nih.gov/pubmed/30354753
11. Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, Imai T, Koepsell H,
Muto S, Vallon V, Nagata D. Unmasking a sustained negative effect of SGLT2 inhibition
on body fluid volume in the rat. Am J Physiol Renal Physiol 315(3), F653-F664 (2018)https://www.ncbi.nlm.nih.gov/pubmed/29790389
12. Murakami T, Akimoto T, Okada M, Hishida E, Sugase T, Miki A, Kohara M, Yoshizawa
H, Masuda T, Kobayashi T, Saito O, Muto S, Nagata D. Valacyclovir neurotoxicity andnephrotoxicity in an elderly patient complicated by hyponatremia. Drug Target Insights
2018 Jun 25;12:1177392818782899. doi: 10.1177/1177392818782899 (2018)https://www.ncbi.nlm.nih.gov/pubmed/30013310

13. Murakami T, Akimoto T, Yamazaki T, Yoshizawa H, Okada M, Miki A, Nakagawa S,Ohara K, Sugase T, Masuda T, Kobayashi T, Saito O, Muto S, Nagata D. Hemolytic
uremic syndrome: An increasingly recognized public health problem. Clin Med Insights
Case Rep 2018 Jul 3;11:1179547618785137. doi: 10.1177/1179547618785137 (2018)https://www.ncbi.nlm.nih.gov/pubmed/30083060
14. Nagayama I, Akimoto T, Ono Y, Ueda Y, Nagata D. Remission of nephrotic syndrome
after surgical intervention for bronchogenic carcinoma: the 10-year follow-up of a patientwith membranous nephropathy. Int Med Case Rep J 11, 167-171 (2018)https://www.ncbi.nlm.nih.gov/pubmed/30104905
15. Ohara K, Masuda T, Murakami T, Imai T, Yoshizawa H, Nakagawa S, Okada M, Miki A,Myoga A, Sugase T, Sekiguchi C, Miyazawa Y, Maeshima A, Akimoto T, Saito O, Muto
S, Nagata D. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid
distribution: A comparison study with furosemide and tolvaptan. Nephrology (Carlton)
2018 Dec 22. doi: 10.1111/nep.13552 (2018)https://www.ncbi.nlm.nih.gov/pubmed/30578654
16. Oka K, Sugase T, Akimoto T, Murakami T, Nagayama I, Kaneko M, Asakura M, Ohara K,Saito O, Nagata D. Kartagener syndrome complicated by immunoglobulin A nephropathy.
Int Med Case Rep J 11, 359-362 (2018)https://www.ncbi.nlm.nih.gov/pubmed/30573994
17. Akimoto T, Muto S, Kutsuwada T, Kutsuwada K, Nagata D. Peritoneal dialysis andmalignancy: An experience with a patient complicated by gastric carcinoma. Clin MedInsights Case Re 2019 Mar 12;12:1179547619835176. doi: 10.1177/1179547619835176(2019)
https://www.ncbi.nlm.nih.gov/pubmed/30886527
18. Masuda T, Ohara K, Nagayama I, Matsuoka R, Murakami T, Nakagawa S, Oka K,
Asakura M, Igarashi Y, Fukaya Y, Miyazawa Y, Maeshima A, Akimoto T, Saito O, Nagata
D. Impact of serum albumin levels on the body fluid response to tolvaptan in chronic
kidney disease patients. Int Urol Nephrol 2019 Jun 3. doi: 10.1007/s11255-019-02180-8(2019)

https://www.ncbi.nlm.nih.gov/pubmed/31161520